The New England journal of medicine
-
Randomized Controlled Trial Multicenter Study Comparative Study
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
The efficacy and safety of nivolumab plus cabozantinib as compared with those of sunitinib in the treatment of previously untreated advanced renal-cell carcinoma are not known. ⋯ Nivolumab plus cabozantinib had significant benefits over sunitinib with respect to progression-free survival, overall survival, and likelihood of response in patients with previously untreated advanced renal-cell carcinoma. (Funded by Bristol Myers Squibb and others; CheckMate 9ER ClinicalTrials.gov number, NCT03141177.).